Seroconversion Rates after COVID-19 Vaccination Amongst Patients with Hematologic Malignancies: Results of a Rapid Vaccination and Evaluation Program in a Minority Rich, Ethnically Diverse Inner City Cohort

It is well established that COVID-19 carries a higher risk of morbidity and mortality in patients (pts) with hematologic malignancies. Emerging data suggests that despite the 3 COVID-19 vaccines with emergency use authorization (EUA) by the FDA inducing high levels of immunity in the general populat...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Lauren C, Gali, Radhika, Thakkar, Astha, Gonzalez-Lugo, Jesus D, Bazarbachi, Abdul Hamid, Rahman, Shafia, Pradhan, Kith, Fehn, Karen, Abreu, Michelly, Kornblum, Noah, Gritsman, Kira, Goldfinger, Mendel, Shastri, Aditi, Mantzaris, Ioannis, Braunschweig, Ira, Halmos, Balazs, Verma, Amit, McCort, Margaret, Bachier-Rodriguez, Lizamarie, Sica, R. Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Hematology. Published by Elsevier Inc. 2021
Materias:
627.Aggressive Lymphomas: Clinical and Epidemiological
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701762/
http://dx.doi.org/10.1182/blood-2021-151309

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8701762/
http://dx.doi.org/10.1182/blood-2021-151309

Ejemplares similares